Covid19 Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19
Verified date | September 2021 |
Source | ETICA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial evaluates the safety, efficacy, and biomarker levels of FDA-approved drug disulfiram in the treatment of adult subjects hospitalized with moderate COVID-19. Disulfiram may limit the hyperinflammatory response associated with COVID-19 and reduce the risk of progression to severe illness. Subjects will be screened and randomized to receive either daily administration of oral disulfiram or placebo for 14 days. Subjects will be followed up on Day 28.
Status | Completed |
Enrollment | 140 |
Est. completion date | September 25, 2021 |
Est. primary completion date | September 10, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years and older |
Eligibility | Inclusion Criteria: Subjects may be enrolled in the study only if all the inclusion criteria are met. 1. Male and female subjects, age 35 or older. 2. Female subjects of childbearing potential must have a negative hCG (in urine or blood) pregnancy test. 3. An International Ethics Committee (IEC) approved informed consent is signed and dated prior to any study-related activities. 4. Willing to abstain from any alcohol or substances containing alcohol (including medications, personal hygiene products, salad dressing) within 24 hours prior to treatment and for 14 days after treatment concludes. 5. Have the ability to understand the requirements of the study and is willing to comply with all study procedures and visits. 6. Respiratory rate: = 30 per minute. 7. Use supplemental O2 via nasal cannula or equivalent. 8. Currently hospitalized = 5 days. 9. PCR test or rapid antigen test confirming SARS-CoV-2. 10. In the opinion of the investigator, able to participate in the study. Exclusion Criteria: Subjects may not be enrolled in the study if any of the exclusion criteria apply. 1. Admission into the Intensive Care Unit (ICU) at screening and baseline. 2. Clinically active Hepatitis. 3. ALT or AST > 3 times the upper limit of normal. 4. Need for invasive or non-invasive ventilation at screening and baseline. 5. Stage 4 severe chronic kidney disease or requiring dialysis or estimated GFR < 30. 6. Known allergy to disulfiram. 7. Treatment with any of the medications listed below within 7 days prior to the baseline visit 1: Amprenavir, Dronabinol, Hydantoins, Metronidazole, Ritonavir, Benznidazole, Dyphylline, Idelalisib, Naltrexone, Sertraline, Chloral Hydrate, Ethanol, Immuno-modulatory drugs, Paclitaxel, Tinidazole, Cocaine, Ethotoin, Ixabepilone, Phenytoin, Tipranavir, Cyclosporine, Fosphenytoin, Lithium, Pimozide, Tranylcypromine, Dasabuvir, Guaifenesin, Mesoridazine, Pirfenidone. 8. Participation in any other interventional trial within 30 days prior to enrollment. 9. Active malignancy (excluding basal cell carcinoma, squamous cell carcinoma, in situ cervical cancer, or adenocarcinoma of the prostate with low or very low-risk categories by NCCN criteria). 10. Any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study. 11. Fully vaccinated for COVID-19 (number of doses as per manufacturer recommendation. |
Country | Name | City | State |
---|---|---|---|
Brazil | ETICA | Salvador | Bahia |
Lead Sponsor | Collaborator |
---|---|
ETICA | Spring Research Foundation |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change from baseline to Day 8 and Day 15 for cytokine IL-18 | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Percentage of subjects requiring supplemental oxygen (WHO Score =4) by Day 8, 15, and 28. | Baseline, Day 8, Day 15 and Day 28 | ||
Other | Percentage of subjects that are discharged by Day 15 and Day 28. | Day 15 and Day 28 | ||
Other | Percentage of subjects that worsened 1 or more points on the WHO Ordinal Scale from baseline through Day 8 and Day 15. | Baseline to Day 8, 15 | ||
Other | Percentage of subjects admitted to the Intensive Care Unit. | Baseline to Day 28 | ||
Other | Percentage of subjects that improved 1 or more points on the WHO Ordinal Scale from baseline to Day 8, 15, and 28. | Baseline to Day 8, 15, and 28 | ||
Other | Change in total neutrophil count from baseline to Day 8 and 15. | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Percent change in total lymphocyte count from baseline to Day 8 and Day 15 | Baseline, Day 8 and Day 15 | ||
Other | Change from baseline to Day 8 and Day 15 for neutrophil-derived circulating free DNA (cf-DNA/NETs) | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for Cytokine TNF-a | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for cytokine IL-1ß | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for cytokine IL-1RA | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for cytokine IL-6 | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for cytokine IL-8 | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for cytokine IL-10 | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for Lactate Dehydrogenase (LDH) | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Change from baseline to Day 8 and Day 15 for D-dimer | Mean change and percent change | Baseline, Day 8 and Day 15 | |
Other | Association between baseline and worst post-baseline WHO score | Baseline to Day 28 | ||
Primary | Time to clinical improvement | Defined as the time from baseline to the first post-baseline assessment with an improvement in WHO score of =1 point. | From enrollment to clinical improvement (1 point or more in the WHO score), up to 28 days | |
Secondary | Mean number of days of supplemental oxygen (WHO score =4) | Baseline to Day 28 | ||
Secondary | Time to discharge from the hospital | From baseline to discharge, up to 28 days. | ||
Secondary | Percentage of subjects that are discharged by Day 8 | At Day 8 | ||
Secondary | Percentage of subjects that worsened 1 or more points on the WHO Ordinal Scale, from baseline to any post baseline assessment through Day 28. | Baseline to Day 28 | ||
Secondary | Mean number of days of non-invasive ventilation or high flow oxygen devices or invasive mechanical ventilation (WHO Score 5 or 6) over the 28-day period. | Baseline to Day 28 | ||
Secondary | Mean number of days subjects were in the Intensive Care Unit (ICU) | Baseline to Day 28 | ||
Secondary | Percentage of subjects that were on non-invasive ventilation or high flow oxygen devices or invasive mechanical ventilation (WHO Score 5 or 6) over the 28-day period. | Baseline to Day 28 | ||
Secondary | 28-day mortality | At Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |